Cellectar Biosciences
Cellectar is a New Jersey radiopharmaceutical company whose iodine-131 phospholipid drug conjugate iopofosine targets the lipid rafts of cancer cells, with a pivotal trial (CLOVER-WaM) in relapsed Waldenström macroglobulinaemia.
Overview
Cellectar Biosciences, based in Florham Park, New Jersey and listed on Nasdaq, develops phospholipid drug conjugates that exploit the lipid rafts abundant on cancer cell membranes to deliver radioisotopes or cytotoxics. Its lead, iopofosine I-131 (CLR 131), delivers iodine-131 and reported its pivotal CLOVER-WaM results in relapsed Waldenström macroglobulinaemia in 2024; earlier studies covered multiple myeloma and paediatric high-grade glioma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- CompanyChongqing Precision Biotech
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyShanghai AbelZeta
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyOncopeptides
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyHeidelberg Pharma
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyAntengene
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyHangzhou Sumgen Biotech
Shares Multiple myeloma and the tag ctgov-sponsor.